Posted by Michael Wonder on 20 Mar 2026
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
20 March 2026 - Today, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine for adult and paediatric patients 12 years and older with previously untreated, stage III or IV classical Hodgkin lymphoma.
The FDA also granted traditional approval to nivolumab for the following indications in adults with relapsed or refractory classical Hodgkin lymphoma:
- After autologous haematopoietic stem cell transplantation (HSCT) and brentuximab vedotin
- After three or more lines of systemic therapy that includes autologous HSCT
